Russian media attention: The price of China's anti-cancer drugs will be 70 times cheaper than that in the United States!

China will not make mistakes like Russia.

An article was published on June 6th by the Russian media "Today's China".

The Sino-US trade war is affecting all fields of China's industry, including pharmaceuticals.

For example, the market value of companies such as Pacific Shuanglin Biopharmaceutical, Beijing Tiantan Biological Products, and China Resources Boya Biopharmaceutical Group has increased by 10% to 15% within a few days.

Russian media cited reports from the "South China Morning Post" saying that as the world's largest healthcare market, the US imported $19 billion worth of medicines and medical equipment from China last year.

What should all this be? Chinese manufacturers are using US tariffs to develop their own production.

China will refuse imports, especially in areas with important strategic significance such as blood and its components.

After all, a country cannot rely on foreign supplies, and China is studying the Russian example on this issue.

China does not want to repeat such mistakes. In recent years, a boom in high-tech companies competing with Western pharmaceutical giants has emerged in China's pharmaceutical market.

Russian media said that in China, these start-ups supported by the government are engaged in drug development for various diseases, including cancer.

For example, Lekang Lifescience Biotechnology Company based in Beijing is one such company. Recently, the US Food and Drug Administration approved human clinical trials for its mRNA vaccine LK101.

Russian experts say this is a historical precedent; before this, anti-cancer drugs developed by China were not allowed to undergo clinical trials in the United States.

The founder of another Beijing startup, ZSky, said that the prices of such Chinese drugs may "decrease exponentially."

The price of an American mRNA anti-cancer vaccine is about $1 million per dose, while the price of six doses produced by ZSky Company in China, including raw materials, consumables, and wages, is less than 100,000 RMB (14,000 USD).

In the context of US trade tariffs, domestic pharmaceutical development and production in China will receive greater impetus.

Affordable drugs for treating the rarest and most serious diseases are expected to appear faster.

Original source: https://www.toutiao.com/article/1834131393855563/

Disclaimer: This article represents the views of the author only.